These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19229603)

  • 41. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome.
    Kaski JC; Consuegra-Sanchez L; Fernandez-Berges DJ; Cruz-Fernandez JM; Garcia-Moll X; Marrugat J; Mostaza J; Toro-Cebada R; González-Juanatey JR; Guzmán-Martínez G;
    Atherosclerosis; 2008 Nov; 201(1):176-83. PubMed ID: 18336825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering.
    Niccoli G; Borovac JA; Vetrugno V; Camici PG; Crea F
    Int J Cardiol; 2017 Jun; 236():107-112. PubMed ID: 28256323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients.
    Nerla R; Di Franco A; Milo M; Pitocco D; Zaccardi F; Tarzia P; Sarullo FM; Villano A; Russo G; Stazi A; Ghirlanda G; Lanza GA; Crea F
    Heart; 2012 Dec; 98(24):1812-6. PubMed ID: 23086971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Which cut-off value of high sensitivity C- reactive protein is more valuable for determining long- term prognosis in patients with acute coronary syndrome?].
    Kiliç T; Ural E; Oner G; Sahin T; Kiliç M; Yavuz S; Kanko M; Kahraman G; Bildirici U; Berki KT; Ural D
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):280-9. PubMed ID: 19666429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
    Scirica BM; Morrow DA; Budaj A; Dalby AJ; Mohanavelu S; Qin J; Aroesty J; Hedgepeth CM; Stone PH; Braunwald E
    J Am Coll Cardiol; 2009 Apr; 53(16):1411-21. PubMed ID: 19371824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
    Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
    Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
    Nicholls SJ; Cavender MA; Kastelein JJ; Schwartz G; Waters DD; Rosenson RS; Bash D; Hislop C
    Cardiovasc Drugs Ther; 2012 Feb; 26(1):71-5. PubMed ID: 22109255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
    Ekman I; Chassany O; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K
    Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
    Morton AC; Rothman AM; Greenwood JP; Gunn J; Chase A; Clarke B; Hall AS; Fox K; Foley C; Banya W; Wang D; Flather MD; Crossman DC
    Eur Heart J; 2015 Feb; 36(6):377-84. PubMed ID: 25079365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
    Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U
    Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.
    Brown DL; Desai KK; Vakili BA; Nouneh C; Lee HM; Golub LM
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):733-8. PubMed ID: 14962945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
    Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
    J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome.
    Mielniczuk LM; Pfeffer MA; Lewis EF; Blazing MA; de Lemos JA; Shui A; Mohanavelu S; Califf RM; Braunwald E
    Am Heart J; 2008 Apr; 155(4):725-31. PubMed ID: 18371483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.